Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 588-594

  Wu, Wei ^a   Zhu, Huayuan ^a   Fu, Yuan ^a   Shen, Wenyi ^a   Xu, Jiadai ^a   Miao, Kourong ^a   Hong, Ming ^a   Xu, Wei ^a   Liu, Peng ^a   Li, Jianyong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; CYLD; Prognosis

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84894472170     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.809077     Document Type: Article

References (40)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Messmer BY, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-764.
3. Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol2Oll;7:285-297.
4. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003;424:801-805.
5. Brummelkamp IR, Nijman SM, Dirac AM, et al. Loss of the cylindromatosistumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003;424:797-801.
6. Trompouki E, Hatzivassiliou E, Tsichritzis I, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003;424:793-796.
7. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004;279:55161-55167.
8. Reiley WW, Zhang M, Jin W, et al. Regulation of I cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006;7:41 1-417.
9. Stokes A, Wakano C, Koblan-Huberson M, et al. IRPA1 is a substrate for deubiquitination by the tumor suppressor CYLD. Cell Signal 2006;18:1584-1594.
10. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008;135:1311-1323.
11. Wu W, Liu P, Li J. Necroptosis: an emerging form of programmed cell death. Crit Rev Oncol Hematol 2012;82:249-258.
12. Jin W, Reiley WR, Lee AJ, et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 2007;282:15884-15893.
13. Reiley WW, Jin W, Lee AJ, et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin- dependent kinase Taki and prevents abnormal I cell responses. J Exp Med 2007;204:1475-1485.
14. Wright A, Reiley WW, Chang M, et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007;13:705-716.
15. Jin W, Chang M, Paul EM, et al. Deubiquitinating enzyme CYLD regulates RANK signaling and osteoclastogenesis. J Clin Invest 2008; 118:1858-1866.
16. Stegmeier F, Sowa ME, Nalepa G, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 2007;104:8869-8874.
17. Gao J, Huo L, Sun X, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008;283:8802-8809.
18. Bignell GR, Warren W, Seal 5, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000;25:160-165.
19. Strobel P, Zettl A, Ren Z, et al. Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am Surg Pathol 2002;26:119-124.
20. Hashimoto K, Mon N, Tamesa I, et al. Analysis ofDNA copynumber aberrations in hepatitis C virus-Associated hepatocellular carcinomas byconventional CGH and array CGH. Mod Pathol 2004;17:617-622.
21. Hirai Y, Kawamata Y, Takeshima N, et al. Conventional and array- based comparative genomic hybridization analyses of novel celllines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int J Oncol 2004;24:977-986.
22. Hellerbrand C, Bumes E, Bataille F, et al. Reducedexpression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007;28:21-27.
23. Massoumi R, Kuphal 5, Hellerbrand C, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009;206:221-232.
24. Annunziata CM, Davis RE, DemchenkoY, et al. Frequent engagement of the classical and alternative NF-lcB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130.
25. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kB pathway in multiple myeloma. Cancer Cell 2007;12:131-144.
26. Espinosa L, Cathelin 5, D'Altri T, et al. The Notch/Hesi pathway sustains NF-kappaB activation through CYLD repression in I cell leukemia. Cancer Cell 2010;18:268-281.
27. Liu P, Xu B, Shen W, et al. Dysregulation of INFct-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 2012;26:1293-300.
28. Xu W, Li ]Y, Wu YJ, et al. Prognostic significance of AIM and 1P53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1071-1077.
29. Pepper C, Hewamana 5, Brennan P, et al. NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 2009;5:1027-1037.
30. Cuni 5, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF- icB pathway is critical for the survival of chronic lymphocytic leukaemia B cells. Leukemia 2004;18:1391-1400.
31. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NFKB activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol 2000;164:2200-2206
32. Iracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-icB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2007;138: 72 1-732.
33. Gagro A, Dasic G, Sabioncello A, et al. Phenotypicanalysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia. Leuk Lymphoma 1997;25:301-311.
34. Lopez-Matas M, Rodriguez-Justo M, Morilla R, et al. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica 2000;85:1140-1145.
35. Stilgenbauer S, Bullinger L, Lichter P, et al. Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course. Leukemia 2002;16: 993-1007.
36. Sheikholeslami MR, Jilani I, Keating M, et al. Variations in the detection of ZAP7O in CLL: comparison with IgVh mutation analysis. Cytometry B Clin Cytom 2006;15;70:270-275.
37. Matrai Z, Lin K, Dennis M, et al. CD38 expression and IGVH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001;97: 1902-1903.
38. Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705-1712.
39. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. Quantification of ZAP7O mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007;53:1757-1766.
40. Sheikholeslami MR, Jilani I, Keating M, et al. Variations in the detection of ZAP7O in CLL: comparison with IgVh mutation analysis. Cytometry B Clin Cytom 2006;70:270-275.